Michael G Goggins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4447859/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2022, 20, e196-e227.	4.4	41
2	Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2022, 20, 2267-2275.e2.	4.4	8
3	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.3	60
4	Endoplasmic stressâ€inducing variants in <scp><i>CPB1</i></scp> and <scp><i>CPA1</i></scp> and risk of pancreatic cancer: A caseâ€control study and metaâ€analysis. International Journal of Cancer, 2022, 150, 1123-1133.	5.1	11
5	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. ELife, 2022, 11, .	6.0	6
6	Urine DNA biomarkers for hepatocellular carcinoma screening. British Journal of Cancer, 2022, 126, 1432-1438.	6.4	15
7	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	1.6	69
8	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.9	8
9	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
10	Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements. Pancreatology, 2021, 21, 613-621.	1.1	27
11	Downregulation of 5â€hydroxymethylcytosine is an early event in pancreatic tumorigenesis. Journal of Pathology, 2021, 254, 279-288.	4.5	12
12	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	4.7	9
13	Abstract 30: Impact of race, sex and age on the risk of pancreatic cancer in new onset diabetics in real-world data. , 2021, , .		Ο
14	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Pancreatology, 2021, 21, 938-941.	1.1	1
15	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.1	8
16	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the <i>ATM</i> Gene. JAMA Oncology, 2021, 7, 1664.	7.1	39
17	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surgical Oncology Clinics of North America, 2021, 30, 773-786.	1.5	16
18	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15

#	Article	IF	CITATIONS
19	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.5	3
20	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. British Journal of Cancer, 2021, 125, 1712-1717.	6.4	4
21	Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1101-1110.	1.7	55
22	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 1161-1169.e5.	4.4	31
23	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
24	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
25	Pancreatic volume does not correlate with histologic fibrosis in adult patients with recurrent acute and chronic pancreatitis. Pancreatology, 2020, 20, 1078-1084.	1.1	5
26	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Letters, 2020, 493, 245-253.	7.2	18
27	Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1487-1500.	7.3	10
28	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
29	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2020, 231, 527-535.e14.	0.5	11
30	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology, 2020, 33, 2544-2563.	5.5	23
31	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	2.5	6
32	Bayesian copy number detection and association in large-scale studies. BMC Cancer, 2020, 20, 856.	2.6	0
33	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Research, 2020, 80, 2804-2817.	0.9	58
34	Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	2.5	5
35	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	7.1	50
36	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.9	5

#	Article	IF	CITATIONS
37	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. Journal of the National Cancer Institute, 2020, 112, 1162-1169.	6.3	114
38	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Laboratory Investigation, 2020, 100, 1003-1013.	3.7	3
39	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Journal of Molecular Diagnostics, 2020, 22, 748-756.	2.8	11
40	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
41	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Modern Pathology, 2019, 32, 1806-1813.	5.5	21
42	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
43	Follow-up of Incidentally Detected Pancreatic Cystic Neoplasms: Do Baseline MRI and CT Features Predict Cyst Growth?. Radiology, 2019, 292, 647-654.	7.3	20
44	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science, 2019, 364, 1156-1162.	12.6	166
45	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	7.0	118
46	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1238-1245.	2.5	48
47	Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements. Journal of Molecular Diagnostics, 2019, 21, 658-676.	2.8	13
48	Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2104-2111.	1.5	64
49	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 153-164.	1.6	135
50	Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology, 2019, 156, 2041-2055.	1.3	52
51	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology, 2019, 156, 1905-1913.	1.3	47
52	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. Journal of Clinical Oncology, 2019, 37, 1070-1080.	1.6	65
53	Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. Journal of Gastrointestinal Surgery, 2019, 23, 477-483.	1.7	8
54	The Gut Microbiome in Pancreatic Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 290-295.	4.4	76

#	Article	IF	CITATIONS
55	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Modern Pathology, 2019, 32, 659-665.	5.5	20
56	Singleâ€cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Journal of Pathology, 2019, 247, 347-356.	4.5	52
57	Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. Oncotarget, 2019, 10, 5592-5604.	1.8	6
58	IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut, 2018, 67, 1652-1662.	12.1	104
59	Mutations in the pancreatic secretory enzymes <i>CPA1</i> and <i>CPB1</i> are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	7.1	65
60	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
61	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
62	Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. International Journal of Epidemiology, 2018, 47, 427-439.	1.9	141
63	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2018, 226, 630-637e1.	0.5	62
64	Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clinical Cancer Research, 2018, 24, 2963-2974.	7.0	55
65	Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. American Journal of Pathology, 2018, 188, 1723-1733.	3.8	32
66	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	2.8	16
67	Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4293-4303.	3.6	15
68	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	4.5	23
69	Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology, 2018, 155, 740-751.e2.	1.3	288
70	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	3.8	0
71	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	4.4	34
72	Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clinical Cancer Research, 2017, 23, 3935-3944.	7.0	63

#	Article	IF	CITATIONS
73	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
74	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut, 2017, 66, 1677-1687.	12.1	134
75	Using an endoscopic distal cap to collect pancreatic fluid fromÂthe ampulla (with video). Gastrointestinal Endoscopy, 2017, 86, 1152-1156.e2.	1.0	10
76	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	2.8	39
77	Genetic analyses of isolated highâ€grade pancreatic intraepithelial neoplasia (HGâ€PanIN) reveal paucity of alterations in <i>TP53</i> and <i>SMAD4</i> . Journal of Pathology, 2017, 242, 16-23.	4.5	108
78	Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2379-2386.	1.5	14
79	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	2.6	24
80	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgery, 2017, 266, 133-141.	4.2	106
81	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
82	Editorial: Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	3
83	Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell, 2017, 32, 824-839.e8.	16.8	97
84	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 2681-2690.	7.0	91
85	IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Oncotarget, 2017, 8, 83370-83383.	1.8	14
86	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 3382-3390.	1.6	316
87	Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Oncotarget, 2017, 8, 50824-50831.	1.8	11
88	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
89	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	4.2	131
90	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	0.9	29

#	Article	IF	CITATIONS
91	Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. Clinical Cancer Research, 2016, 22, 5141-5151.	7.0	43
92	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29
93	Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. Pancreatology, 2016, 16, 869-872.	1.1	3
94	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
95	Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Science, 2016, 107, 569-575.	3.9	106
96	Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2016, 11, e0164195.	2.5	15
97	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
98	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. American Journal of Surgical Pathology, 2015, 39, 1730-1741.	3.7	626
99	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. PLoS ONE, 2015, 10, e0117574.	2.5	29
100	A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology, 2015, 15, 387-391.	1.1	32
101	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell, 2015, 161, 1345-1360.	28.9	175
102	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	2.2	64
103	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	1.3	376
104	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
105	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
106	Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. European Journal of Radiology, 2015, 84, 575-580.	2.6	19
107	Classifying pancreatic cancer using gene expression profiling. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 613-614.	17.8	8
108	Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointestinal Endoscopy, 2015, 82, 812-818.	1.0	43

#	Article	IF	CITATIONS
109	Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut, 2015, 64, 1783-1789.	12.1	157
110	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine, 2015, 17, 569-577.	2.4	231
111	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clinical and Translational Gastroenterology, 2014, 5, e62.	2.5	28
112	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
113	Targeted nextâ€generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Journal of Pathology, 2014, 233, 217-227.	4.5	308
114	A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas, 2014, 43, 331-337.	1.1	276
115	Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clinical Cancer Research, 2014, 20, 6200-6211.	7.0	38
116	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
117	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
118	Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Medicine, 2014, 6, 61.	8.2	170
119	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. Cancer Research, 2014, 74, 3381-3389.	0.9	207
120	Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. Annals of Surgical Oncology, 2014, 21, 3668-3674.	1.5	45
121	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgical Oncology, 2013, 20, 3802-3808.	1.5	158
122	Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 6544-6555.	7.0	129
123	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut, 2013, 62, 339-347.	12.1	672
124	Mutant <i>GNAS</i> detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
125	An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic Cancer in the General Population. PLoS ONE, 2013, 8, e72311.	2.5	120
126	<i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442

#	Article	IF	CITATIONS
127	Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2012, 18, 700-712.	7.0	69
128	MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias. Clinical Cancer Research, 2012, 18, 981-992.	7.0	198
129	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
130	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.3	570
131	Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2′-Deoxycytidine. PLoS ONE, 2012, 7, e43456.	2.5	24
132	Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma Journal of Clinical Oncology, 2012, 30, 164-164.	1.6	0
133	Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay Journal of Clinical Oncology, 2012, 30, 151-151.	1.6	0
134	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	13.7	2,155
135	Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2011, 17, 4341-4354.	7.0	154
136	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
137	Markers of Pancreatic Cancer: Working Toward Early Detection. Clinical Cancer Research, 2011, 17, 635-637.	7.0	39
138	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
139	In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Laboratory Investigation, 2010, 90, 665-673.	3.7	14
140	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics, 2010, 42, 224-228.	21.4	539
141	Pancreatic cancer <i>DNMT1</i> expression and sensitivity to <i>DNMT1</i> inhibitors. Cancer Biology and Therapy, 2010, 9, 321-329.	3.4	54
142	Importance of Age of Onset in Pancreatic Cancer Kindreds. Journal of the National Cancer Institute, 2010, 102, 119-126.	6.3	193
143	Exomic Sequencing Identifies <i>PALB2</i> as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
144	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clinical Cancer Research, 2009, 15, 7737-7743.	7.0	195

#	Article	IF	CITATIONS
145	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 2009, 41, 986-990.	21.4	597
146	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
147	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	3.0	16
148	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. Seminars in Oncology, 2007, 34, 303-310.	2.2	89
149	Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clinical Gastroenterology and Hepatology, 2006, 4, 766-781.	4.4	493
150	Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer, 2006, 107, 251-257.	4.1	43
151	Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 704-710.	2.5	133
152	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. American Journal of Surgical Pathology, 2006, 30, 1067-76.	3.7	261
153	Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biology and Therapy, 2005, 4, 728-733.	3.4	83
154	Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms. Cancer Biology and Therapy, 2005, 4, 596-601.	3.4	24
155	Molecular Markers of Early Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4524-4531.	1.6	212
156	Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds. Cancer Research, 2004, 64, 2634-2638.	0.9	595
157	Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biology and Therapy, 2004, 3, 651-656.	3.4	35
158	Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene, 2004, 23, 9042-9051.	5.9	103
159	Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clinical Gastroenterology and Hepatology, 2004, 2, 606-621.	4.4	431
160	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2004, 164, 903-914.	3.8	190
161	Overexpression of S100A4 in Pancreatic Ductal Adenocarcinomas Is Associated with Poor Differentiation and DNA Hypomethylation. American Journal of Pathology, 2002, 160, 45-50.	3.8	203
162	BRCA2 and predisposition to pancreatic and other cancers. Expert Reviews in Molecular Medicine, 2001, 3, 1-10.	3.9	10

#	Article	IF	CITATIONS
163	Can we screen high-risk individuals to detect early pancreatic carcinoma?. Journal of Surgical Oncology, 2000, 74, 243-248.	1.7	62
164	Tumor-Suppressor genes in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 383-391.	2.0	40